83 search results for: burden of disease
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD
In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson goes on to explore how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the potential importance of early and effective therapeutic intervention to alter disease progression
ADVENT at CEORL-HNS 2026
Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.
Understanding the Clinical Impact of Mucus Plugs in COPD
Understand the pathophysiology and clinical relevance of mucus plugs in COPD that ultimately contribute to worse outcomes for patients.
Unpacking the Significant Burdens of Atopic Dermatitis
Dr. Lawrence Eichenfield shares the cumulative burdens faced by patients with atopic dermatitis.
ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD
Join Drs. April Armstrong and Lisa Beck for a conversation around the long-term burden and effects of AD. They will discuss the underlying pathophysiology of AD and how early intervention and disease modification may impact disease course.
Decoding the Clinical Puzzle: Navigating Diagnostic Complexity Across Inflammatory Skin Diseases
Dr Sarina Elmariah highlights the clinical challenges in diagnosing inflammatory skin diseases, using prurigo nodularis as a case study. Drs Culton, Eichenfield, and Hawkes then join in to discuss additional challenges and complexities when diagnosing other skin diseases.
ADVENT on Air: OCS in CRSwNP Podcast
Listen to experts, Dr. Amber Luong and Dr. Marjolein Cornet, discuss the significant burden of oral corticosteroid (OCS) use in chronic rhinosinusitis with nasal polyps (CRSwNP) and its short-term, long-term, and cumulative risks, particularly for patients with coexisting conditions like asthma. Experts highlight the need for improved multidisciplinary approaches and OCS-sparing strategies to optimize patient care.
Inside the Hive: Type 2 Inflammatory Pathways in Chronic Spontaneous Urticaria
Join Dr. Jason Hawkes in discussing the burden of CSU and how type 2 inflammation contributes to the development of chronic wheals (hives) and angioedema
How Biologic Therapy May Lead to Disease Modification in Infants and Children with Atopic Dermatitis
The underlying pathophysiology of atopic dermatitis (AD) is driven by dysregulation of type 2 immunity that contributes to skin barrier dysfunction. AD typically develops very early in life and children with AD often develop other atopic conditions such as food allergy, asthma, and allergic rhinitis in a progression called the atopic march. Early treatment may help reduce the atopic march and other comorbidities to lessen the lifetime burden created by these diseases. There may even be a window of opportunity for disease modification.
The Burden in Patients with CRSwNP and Coexisting Asthma
This video supports improved clinical awareness and encourages comprehensive care strategies for patients living with both CRSwNP and asthma.
